As a valuable partner focused on antibody-drug conjugates (ADCs) research and development, Creative Biolabs recently launched a powerful ADC payload called amatoxin based on their exclusive “DrugLnk” organic synthesis platform.
Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents, consisting of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. The toxic payload drug as an essential component of any therapeutic ADC plays a decisive role in determining its efficacy.
“In reality, not every toxin is suitable to be used as an ADC payload. To serve this very purpose, the toxins must exert extremely high cytotoxic efficacy and adequate plasma stability with a small size to minimize the risk of immunogenicity. Since current ADC strategies rely on the internalization of the toxin conjugates, the targets of the payloads must be located inside the cell.” Said a scientist from Creative Biolabs.
https://www.creative-biolabs.com/adc/amatoxins.htm